ReviewCNS drugs2005
Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.
Review in CNS drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 73 citations in OpenAlex.
- Review
- Serological Cross-Reactivity in Zoonotic Flaviviral Infections of Medical Importance.Antibodies (Basel, Switzerland) · 2023Review
- Article
- Seroprevalence survey of arboviruses in workers from Tuscany, Italy.La Medicina del lavoro · 2018Article
- Tick-borne encephalitis virus induces chemokine RANTES expression via activation of IRF-3 pathway.Journal of neuroinflammation · 2016Article
- Clinical course and sequelae for tick-borne encephalitis among children in South Moravia (Czech Republic).European journal of pediatrics · 2015Article
- Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses.Clinical and experimental vaccine research · 2014Review
- Powassan virus encephalitis, Minnesota, USA.Emerging infectious diseases · 2012Article
- Tick-borne encephalitis virus in dogs--is this an issue?Parasites & vectors · 2011Review
- Coinfection with Rickettsia helvetica and Herpes Simplex Virus 2 in a Young Woman with Meningoencephalitis.Case reports in infectious diseases · 2011Article
- Prevalence of tick-borne encephalitis virus in ticks from southern Korea.Journal of veterinary science · 2010Article
- Determinants of tick-borne encephalitis in counties of southern Germany, 2001-2008.International journal of health geographics · 2010Article
- Rickettsia helvetica in patient with meningitis, Sweden, 2006.Emerging infectious diseases · 2010Article
- Tick-borne encephalitis: from epidemiology to vaccination recommendations in 2007. New issues--best practices.Wiener medizinische Wochenschrift (1946) · 2007Article
- Tickborne encephalitis virus, northeastern Italy.Emerging infectious diseases · 2006Article
- Genetics of Streptomyces rimosus, the oxytetracycline producer.Microbiology and molecular biology reviews : MMBR · 2006Review
- Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue.Journal of neurovirology · 2006Article
- Tick-borne encephalitis--a European health challenge. Conference report of the 8th meeting of the International Scientific Working Group on Tick-borne Encephalitis (ISW TBE).Wiener medizinische Wochenschrift (1946) · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne encephalopathies constitute a broad range of infectious diseases affecting the brain and other parts of the CNS. The causative agents are both viral and bacterial. This review focuses on the current most important tick-borne human diseases: tick-borne encephalitis (TBE; including Powassan encephalitis) and Lyme borreliosis. Rocky Mountain spotted fever (RMSF) and Colorado tick fever (CTF), less common tick-borne diseases associated with encephalopathy, are also discussed. TBE is the most important flaviviral infection of the CNS in Europe and Russia, with 10 000-12 000 people diagnosed annually. The lethality of TBE in Europe is 0.5% and a post-encephalitic syndrome is seen in over 40% of affected patients, often producing a pronounced impairment in quality of life. There is no specific treatment for TBE. Two vaccines are available to prevent infection. Although these have a good protection rate and good efficacy, there are few data on long-term immunity. Lyme borreliosis is the most prevalent tick-borne disease in Europe and North America, with >50 000 cases annually. Localised early disease can be treated with oral phenoxymethylpenicillin (penicillin V), doxycycline or amoxicillin. The later manifestations of meningitis, arthritis or acrodermatitis can be treated with oral doxycycline, oral amoxicillin or intravenous ceftriaxone; intravenous benzylpenicillin (penicillin G) or cefotaxime can be used as alternatives. The current use of vaccines against Lyme borreliosis in North America is under discussion, as the LYMErix vaccine has been withdrawn from the market because of possible adverse effects, for example, arthritis. RMSF and CTF appear only in North America. RMSF is an important rickettsial disease and is effectively treated with doxycycline. There is no treatment or preventative measure available for CTF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.